Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
γδ T Cell Immunotherapy for Treatment of Liver Cancer
NCT03183219Phase 2Completed
- Sponsor
- Fuda Cancer Hospital
- Start
- Jun 2017
- Primary completion
- Jan 2018
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic Vγ9Vδ2 T cell therapy in liver cancer, sponsored by Fuda Cancer Hospital. Started Jun 2017; status: completed.
02
Drugs
allogeneic Vγ9Vδ2 T cell therapy
03
Conditions
liver cancer
Beyond the preview
Go deeper on NCT03183219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03183219.